Jean-charles C. Soria
Expertise in
14
conditions

Jean-charles C. Soria

Gustave Roussy
Villejuif, FR 
Expertise in
14
conditions
Gustave Roussy
Villejuif, FR 
OverviewLocationsClinical Research

Overview

Jean-charles Soria practices in Villejuif, France. Soria is highly rated in 14 conditions, according to our data. Their top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Squamous Cell Lung Carcinoma, EGFR Positive Lung Cancer, and Tissue Biopsy.

Their clinical research consists of co-authoring 418 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Locations

Gustave Roussy
Villejuif, 94805, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Phase 1/2 Study of TAS-120 in Patients With Advanced Solid Tumors Harboring FGF/FGFR Aberrations
Phase 1/2 Study of TAS-120 in Patients With Advanced Solid Tumors Harboring FGF/FGFR Aberrations
Enrollment Status: Completed
Publish Date: March 27, 2025
Intervention Type: Drug
Study Drug: TAS-120
Study Phase: Phase 1/Phase 2
A Phase I, Open-Label, Non-Randomized, Dose-Escalating Safety, Tolerability and Pharmacokinetic Study of TAS-114 in Combination With S-1 in Patients With Advanced Solid Tumors
A Phase I, Open-Label, Non-Randomized, Dose-Escalating Safety, Tolerability and Pharmacokinetic Study of TAS-114 in Combination With S-1 in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: September 04, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Study of HSP90 Inhibitor AT13387 Alone and in Combination With Crizotinib in the Treatment of Non-small Cell Lung Cancer (NSCLC)
A Study of HSP90 Inhibitor AT13387 Alone and in Combination With Crizotinib in the Treatment of Non-small Cell Lung Cancer (NSCLC)
Enrollment Status: Completed
Publish Date: August 02, 2024
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types
Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types
Enrollment Status: Completed
Publish Date: February 28, 2024
Intervention Type: Drug
Study Drug: Nivolumab
Study Phase: Phase 2
Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types
Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types
Enrollment Status: Completed
Publish Date: February 28, 2024
Intervention Type: Drug
Study Drug: Pembrolizumab
Study Phase: Phase 2
Intergroup Trial UNICANCER UC 0105-1305/ IFCT 1301: SAFIR02_Lung - Evaluation of the Efficacy of High Throughput Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Non-small Cell Lung Cancer
Intergroup Trial UNICANCER UC 0105-1305/ IFCT 1301: SAFIR02_Lung - Evaluation of the Efficacy of High Throughput Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Non-small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: January 10, 2024
Intervention Type: Drug
Study Drugs: AZD2014, AZD4547, AZD5363, AZD8931, Selumetinib, Vandetanib, Standard Maintenance, Pemetrexed, Durvalumab, Savolitinib, Olaparib
Study Phase: Phase 2
View 5 Less Clinical Trials

418 Total Publications

Erratum: Immobilization Time for Conservative Treatment of Distal Radial Fractures in Elderly Patients: A Randomized Controlled Trial.
Erratum: Immobilization Time for Conservative Treatment of Distal Radial Fractures in Elderly Patients: A Randomized Controlled Trial.
Journal: The Journal of bone and joint surgery. American volume
Published: September 17, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Soria's expertise for a condition
ConditionClose
View All 8 Advanced Conditions
View All 41 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile